

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**204325Orig1s000**

**OFFICER/EMPLOYEE LIST**

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH

**DATE:** September 12, 2017

**TO:** Administrative file for NDA 204325

**FROM:** Brendan Muoio, Regulatory Health Project Manager  
Division of Psychiatry Products, Office of Drug Evaluation I

**SUBJECT:** Officer/Employee List for NDA 204325

**APPLICATION/DRUG:** NDA 204325, Adzenys ER, amphetamine, extended-release oral suspension

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Bansil, Shalini  
Bradshaw, Christine  
Dinatale, Miriam  
Dorantes, Angelica  
Farchione, Tiffany  
Fischer, Bernard  
Holmes, Loretta  
Hutchins, Shawna  
Kumi, Kofi A  
Liedtka, Jane  
Mathis, Mitchell  
McGhee, Laura  
Muoio, Brendan  
Ou, Mei  
Ponta, Andrei  
Rao, Deepa  
Redwood, Susan  
Sachs, Hari  
Stone, Marc  
Wilson, Wendy  
Wu, Ta-Chen  
Zhu, Hao